A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia
NCT03692052
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Thalassemia
Interventions
DRUG:
AG-348
Sponsor
Agios Pharmaceuticals, Inc.